Beth Israel Comprehensive Cancer Center — New York, New York

Beth Israel Comprehensive Cancer Center is a clinical research site located in New York, New York, United States 10011-5903.

Crixeo Health Trust Score: 74/100 (FAIR). This profile has not yet been claimed by the site owner.

Beth Israel Comprehensive Cancer Center has participated in 7 clinical trials.

Therapeutic areas: Lymphoma, Non-Hodgkin, Non-small Cell Lung Cancer Stage IIIB/IV, Non-small Cell Lung Cancer Metastatic.

Sponsors: Pfizer, Beth Israel Medical Center, Celgene.

Sponsor Feasibility Report

Trust Score: 74/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Beth Israel Comprehensive Cancer Center?

Beth Israel Comprehensive Cancer Center has a Crixeo Trust Score of 74/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Beth Israel Comprehensive Cancer Center conducted?

Beth Israel Comprehensive Cancer Center has 7 clinical trials on record. Their work covers Lymphoma, Non-Hodgkin, Non-small Cell Lung Cancer Stage IIIB/IV, Non-small Cell Lung Cancer Metastatic.

Is Beth Israel Comprehensive Cancer Center accredited by Crixeo Health?

Yes — Beth Israel Comprehensive Cancer Center holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Beth Israel Comprehensive Cancer Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.